FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease

Radiographics

Volumn 30, Issue 1, 2010, Pages 269-291

  Paes, Fabio M ^a   Kalkanis, Dimitrios G ^a   Sideras, Panagiotis A ^a   Serafini, Aldo N ^a  

^a JACKSON MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HODGKIN DISEASE; HUMAN; IMAGE SUBTRACTION; LYMPH NODE; MALE; METHODOLOGY; MIDDLE AGED; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; SCINTISCANNING;

ADULT; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; LYMPH NODES; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 77950133057     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.301095088     Document Type: Article

References (89)

1. American Cancer Society. Cancer Facts & Figures 2008. Available at: http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf. Accessed March 11, 2009.
2. Zucca E, Conconi A, Cavalli F. Treatment of extranodal lymphomas. Best Pract Res Clin Haematol 2002;15:533-547.
3. Gurney KA, Cartwright RA. Increasing incidence and descriptive epidemiology of extranodal non-Hodgkin lymphoma in parts of England and Wales. Hematol J 2002;3:95-104.
4. Groves FD, Linet MS, Travis LB, Devesa SS. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 2000; 92:1240-1251.
5. Glass AG, Karnell LH, Menck HR. The National Cancer Data Base report on non-Hodgkin's lymphoma. Cancer 1997;80:2311-2320.
6. Kostakoglu L, Goldsmith SJ. Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears? Eur J Nucl Med 2000;27:1564-1578.
7. Seam P, Juweid ME, Cheson BD. The role of FDG PET scans in patients with lymphoma. Blood 2007; 110:3507-3516.
8. Fougère C, Hundt W, Brockel N, et al. Value of PET/CT versus PET and CT performed as separate investigations in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2006;33:1417-1425.
9. Terasawa T, Nihashi T, Hotta T, Nagai H. 18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review. J Nucl Med 2007;49:13-21.
10. Freudenberg LS, Antoch G, Schutt P, et al. FDG PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 2004;31:325-329.
11. Raanani P, Shasha Y, Perry C, et al. Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era? Ann Oncol 2005;17:117-122.
12. Kwee TC, Kwee RM, Nievelstein RA. Imaging in staging of malignant lymphoma: a systematic review. Blood 2008;111:504-516.
13. Isasi CR, Lu P, Blaufox MD. A metaanalysis of 18F-2-deoxy-2-fluoro-d-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 2005;104:1066-1074.
14. Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, Hooft L, Riphagen II, Huijgens PC. 18F-fluorodeoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica 2006;91:522-529.
15. Schaefer NG, Hany TF, Taverna C, et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging- do we need contrast-enhanced CT? Radiology 2004; 232:823-829.
16. Pelosi E, Pregno P, Penna D, et al. Role of wholebody [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/ CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma. Radiol Med (Torino) 2008;113:578-590.
17. Moog F, Bangerter M, Diederichs CG, et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 1998;206:475-481.
18. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586.
19. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25:571-578.
20. Schoder H, Moskowitz C. PET imaging for response assessment in lymphoma: potential and limitations [viii.]. Radiol Clin North Am 2008;46: 225-241.
21. Schoder H, Noy A, Gonen M, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 2005;23:4643-4651.
22. Elstrom R, Guan L, Baker G, et al. Utility of FDG PET scanning in lymphoma by WHO classification. Blood 2003;101:3875-3876.
23. Kako S, Izutsu K, Ota Y, et al. FDG PET in Tcell and NK-cell neoplasms. Ann Oncol 2007;18: 1685-1690.
24. Allen-Auerbach M, de Vos S, Czernin J. The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients [vii.]. Radiol Clin North Am 2008;46:199-211.
25. Hutchings M, Loft A, Hansen M, Ralfkiaer E, Specht L. Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake. Hematol Oncol 2006;24: 146-150.
26. Perry C, Herishanu Y, Metzer U, et al. Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma. Eur J Haematol 2007;79:205-209.
27. Rousseau C, Bourbouloux E, Campion L, et al. Brown fat in breast cancer patients: analysis of serial (18)F-FDG PET/CT scans. Eur J Nucl Med Mol Imaging 2006;33:785-791.
28. Christensen CR, Clark PB, Morton KA. Reversal of hypermetabolic brown adipose tissue in F-18 FDG PET imaging. Clin Nucl Med 2006;31:193-196.
29. Garcia CA, Van Nostrand D, Atkins F, et al. Reduction of brown fat 2-deoxy-2-[F-18]fluoro-d-glucose uptake by controlling environmental temperature prior to positron emission tomography scan. Mol Imaging Biol 2006;8:24-29.
30. Williams G, Kolodny GM. Method for decreasing uptake of 18F-FDG by hypermetabolic brown adipose tissue on PET. AJR Am J Roentgenol 2008;190: 1406-1409.
31. Gelfand MJ, O'Hara SM, Curtwright LA, Maclean JR. Pre-medication to block [(18)F]FDG uptake in the brown adipose tissue of pediatric and adolescent patients. Pediatr Radiol 2005;35:984-990.
32. Parysow O, Mollerach AM, Jager V, Racioppi S, San Roman J, Gerbaudo VH. Low-dose oral propranolol could reduce brown adipose tissue F-18 FDG uptake in patients undergoing PET scans. Clin Nucl Med 2007;32:351-357.
33. Even-Sapir E, Lievshitz G, Perry C, Herishanu Y, Lerman H, Metser U. Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with non-Hodgkin lymphoma and Hodgkin's disease [vii.]. Radiol Clin North Am 2007;45: 697-709.
34. Cook GJ. Pitfalls in PET/CT interpretation. Q J Nucl Med Mol Imaging 2007;51:235-243.
35. Lin C, Itti E, Haioun C, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med 2007;48:1626-1632.
36. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50:122S-150S.
37. Boellaard R, Oyen WJ, Hoekstra CJ, et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multicentre trials. Eur J Nucl Med Mol Imaging 2008;35: 2320-2333.
38. Byun BH, Na II, Cheon GJ, et al. Clinical significance of 18F-FDG uptake by primary sites in patients with diffuse large B cell lymphoma in the head and neck: a pilot study. Ann Nucl Med 2008;22: 645-651.
39. Zucca E, Roggero E, Bertoni F, Conconi A, Cavalli F. Primary extranodal non-Hodgkin's lymphomas. II. Head and neck, central nervous system and other less common sites. Ann Oncol 1999;10:1023-1033.
40. Mok TS, Steinberg J, Chan AT, et al. Application of the international prognostic index in a study of Chinese patients with non-Hodgkin's lymphoma and a high incidence of primary extranodal lymphoma. Cancer 1998;82:2439-2448.
41. Lopez-Guillermo A, Colomo L, Jimenez M, et al. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol 2004;23:2797-2804.
42. Blodgett TM, Fukui MB, Snyderman CH, et al. Combined PET-CT in the head and neck. I. Physiologic, altered physiologic, and artifactual FDG uptake. RadioGraphics 2005;25:897-912.
43. Fukui MB, Blodgett TM, Snyderman CH, et al. Combined PET-CT in the head and neck. II. Diagnostic uses and pitfalls of oncologic imaging. RadioGraphics 2005;25:913-930.
44. Karantanis D, Subramaniam RM, Peller PJ, et al. The value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma. Clin Lymphoma Myeloma 2008;8:94-99.
45. Economopoulos T, Fountzilas G, Kostourou A, et al. Primary extranodal non-Hodgkin's lymphoma of the head and neck in adults: a clinicopathological comparison between tonsillar and non-tonsillar lymphomas (Hellenic co-Operative Oncology Group). Anticancer Res 1998;18:4655-4660.
46. Rosado MF, Morgensztern D, Peleg M, Lossos IS. Primary diffuse large cell lymphoma of the mandible. Leuk Lymphoma 2004;45:1049-1053.
47. Nakamoto Y, Tatsumi M, Hammoud D, Cohade C, Osman MM, Wahl RL. Normal FDG distribution patterns in the head and neck: PET/CT evaluation. Radiology 2005;234:879-885.
48. Choi JY, Lee KS, Kim HJ, et al. Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: clinical significance and improved characterization. J Nucl Med 2006;47:609-615.
49. Karantanis D, Bogsrud TV, Wiseman GA, et al. Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland. J Nucl Med 2007;48: 896-901.
50. Valenzuela AA, Allen C, Grimes D, Wong D, Sullivan TJ. Positron emission tomography in the detection and staging of ocular adnexal lymphoproliferative disease. Ophthalmology 2006;113:2331-2337.
51. Haque S, Law M, Abrey LE, Young RJ. Imaging of lymphoma of the central nervous system, spine, and orbit [ix]. Radiol Clin North Am 2008;46:339-361.
52. Palmedo H, Urbach H, Bender H, et al. FDG PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up. Eur J Nucl Med Mol Imaging 2006;33:164-168.
53. Guermazi A, Brice P, de Kerviler EE, et al. Extranodal Hodgkin disease: spectrum of disease. RadioGraphics 2001;21:161-179.
54. Nieuwenhuizen L, Verzijlbergen FJ, Wiltink E, Grutters JC, Biesma DH. A possible role of 18F-FDG positron-emission tomography scanning in the early detection of rituximab-induced pneumonitis in patients with non-Hodgkin's lymphoma. Haematologica 2008;93:1267-1269.
55. Chang CY, Tsai CS, Peng YJ, Huang WS. Large B-cell lymphoma mimicking ischemic heart disease demonstrated by F-18 fluorodeoxyglucose PET/CT in a heart transplant patient. J Nucl Cardiol 2007; 14:754-757.
56. Buchmann I, Wandt H, Wahl A, Reske SN. FDG PET for imaging pericardial manifestations of Hodgkin lymphoma. Clin Nucl Med 2003;28:760-761.
57. Weijs LE, Arsos G, Baarslag HJ, Wittebol S, de Klerk JM. Pericardial involvement in a non-Hodgkin lymphoma patient: coregistered FDG PET and CT imaging. Eur Heart J 2007;28:2698.
58. Jerusalem G, Beguin Y, Fassotte MF, et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 2003;14:123-130.
59. Kyoung Jung H, Kim EK, Yun M, Jung Kim M, Young Kwak J. Bilateral breast involvement in Burkitt's lymphoma detected only by FDG PET. Clin Imaging 2006;30:57-59.
60. Bakheet SM, Bakheet R, Ezzat A, Tulbah A, Durakovic A, Hussain S. F-18 FDG positron emission tomography in primary breast non-Hodgkin's lymphoma. Clin Nucl Med 2001;26:299-301.
61. Nihashi T, Hayasaka K, Itou T, et al. Findings of fluorine-18-FDG PET in extranodal origin lymphoma in three cases of diffuse large B cell type lymphoma. Ann Nucl Med 2006;20:689-693.
62. Kumar R, Xiu Y, Dhurairaj T, Yu JQ, Alavi A, Zhuang H. F-18 FDG positron emission tomography in non-Hodgkin lymphoma of the breast. Clin Nucl Med 2005;30:246-248.
63. Moog F, Kotzerke J, Reske SN. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. J Nucl Med 1999;40:1407-1413.
64. Pelosi E, Penna D, Deandreis D, et al. FDG PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management. Q J Nucl Med Mol Imaging 2008;52:9-16.
65. Even-Sapir E. Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. J Nucl Med 2005;46:1356-1367.
66. Pakos EE, Fotopoulos AD, Ioannidis JP. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 2005;46:958-963.
67. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105:3768-3785.
68. Kumar R, Xiu Y, Zhuang HM, Alavi A. 18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma. Br J Dermatol 2006;155:357-363.
69. Kuo PH, McClennan BL, Carlson K, et al. FDG PET/CT in the evaluation of cutaneous T-cell lymphoma. Mol Imaging Biol 2008;10:74-81.
70. Bishu S, Quigley JM, Schmitz J, et al. F-18-fluorodeoxy-glucose positron emission tomography in the assessment of peripheral T-cell lymphomas. Leuk Lymphoma 2007;48:1531-1538.
71. Watanabe N, Kato H, Murakami J, et al. FDG PET imaging in cutaneous anaplastic large cell lymphoma. Clin Nucl Med 2006;31:564-565.
72. Samuel LM, White J, Lessells AM, Roddie H, Matheson LM. Primary non-Hodgkins lymphoma of muscle. Clin Oncol (R Coll Radiol) 1999;11:49-51.
73. Kumar R, Xiu Y, Mavi A, El-Haddad G, Zhuang H, Alavi A. FDG PET imaging in primary bilateral adrenal lymphoma: a case report and review of the literature. Clin Nucl Med 2005;30:222-230.
74. Metser U, Goor O, Lerman H, Naparstek E, EvenSapir E. PET-CT of extranodal lymphoma. AJR Am J Roentgenol 2004;182:1579-1586.
75. de Jong PA, van Ufford HM, Baarslag HJ, et al. CT and 18F-FDG PET for noninvasive detection of splenic involvement in patients with malignant lymphoma. AJR Am J Roentgenol 2009;192:745-753.
76. Rini JN, Leonidas JC, Tomas MB, Palestro CJ. 18FFDG PET versus CT for evaluating the spleen during initial staging of lymphoma. J Nucl Med 2003; 44:1072-1074.
77. Noronha V, Shafi NQ, Obando JA, Kummar S. Primary non-Hodgkin's lymphoma of the liver. Crit Rev Oncol Hematol 2005;53:199-207.
78. Fishman EK, Kuhlman JE, Jones RJ. CT of lymphoma: spectrum of disease. RadioGraphics 1991; 11:647-669.
79. Dodd GD. Lymphoma of the hollow abdominal viscera. Radiol Clin North Am 1990;28:771-783.
80. Taal BG, Burgers JM, van Heerde P, Hart AA, Somers R. The clinical spectrum and treatment of primary non-Hodgkin's lymphoma of the stomach. Ann Oncol 1993;4:839-846.
81. Radan L, Fischer D, Bar-Shalom R, et al. FDG avidity and PET/CT patterns in primary gastric lymphoma. Eur J Nucl Med Mol Imaging 2008;35: 1424-1430.
82. Levine MS, Rubesin SE, Pantongrag-Brown L, Buck JL, Herlinger H. Non-Hodgkin's lymphoma of the gastrointestinal tract: radiographic findings. AJR Am J Roentgenol 1997;168:165-172.
83. Sam JW, Levine MS, Farner MC, Schuster SJ, Alavi A. Detection of small bowel involvement by mantle cell lymphoma on F-18 FDG positron emission tomography. Clin Nucl Med 2002;27:330-333.
84. Phongkitkarun S, Varavithya V, Kazama T, et al. Lymphomatous involvement of gastrointestinal tract: evaluation by positron emission tomography with (18)F-fluorodeoxyglucose. World J Gastroenterol 2005;11:7284-7289.
85. Souza FF, Israel DA. PET/CT appearance of nonHodgkin lymphoma of the vermiform appendix. Clin Nucl Med 2008;33:694-696.
86. Freeman C. Occurrence and prognosis of extranodal lymphomas. Cancer 1972;29:252-260.
87. Ezzat A, Jamshed A, Khafaga Y, et al. Primary pancreatic non-Hodgkin's lymphomas. J Clin Gastroenterol 1996;23:109-112.
88. Glazer HS, Lee JK, Balfe DM, Mauro MA, Griffith R, Sagel SS. Non-Hodgkin lymphoma: computed tomographic demonstration of unusual extranodal involvement. Radiology 1983;149:211-217.
89. Fonseca R, Habermann TM, Colgan JP, et al. Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer 2000;88:154-161.